指南与共识技术与安全PETCTMR

PET/CT与PET临床实践指南推荐意见的质量与一致性:一项系统性评价

Quality and consistency of clinical practice guideline recommendations for PET/CT and PET: a systematic appraisal.
指南 / 共识 · Eur Radiol · 2023-06-14

该研究系统检索并评价了2008至2021年发表的35部PET影像相关指南,采用AGREE II工具评估方法学质量并比较18F-FDG PET/CT适应证推荐的一致性。指南在范围与目的(中位80.6%)和表达清晰性(中位75%)方面表现较好,但在应用性方面较差(中位27.1%)。在13种癌症的48项适应证中,有10项(20.1%)推荐方向存在明显不一致。

要点

  • PET影像指南方法学质量参差,应用性领域得分最低(中位27.1%)。
  • 13种癌症48项适应证中,10项(20.1%)对FDG PET/CT是否支持的推荐方向不一致。
  • 不一致涉及头颈、结直肠、食管、乳腺、宫颈、卵巢、胰腺及肉瘤等8种癌症。

核心结论

  • 现行PET影像指南方法学质量不一且推荐意见存在相当程度的不一致,需改进指南制定方法、综合高质量证据并采用标准术语。

研究设计与样本

  • 系统评价:检索PubMed、EMBASE、四个指南数据库及Google Scholar,纳入2008至2021年发表的35部基于证据的PET、PET/CT或PET/MR临床实践指南,采用AGREE II工具评估质量并比较18F-FDG PET/CT适应证推荐。

诊断标准与关键数值

  • 采用AGREE II评估方法学质量:范围与目的领域中位80.6%(IQR 77.8-83.3%),表达清晰性中位75%(IQR 69.4-83.3%),应用性中位27.1%(IQR 22.9-37.5%)。
  • 比较13种癌症的48项适应证推荐,其中10项(20.1%)涉及8种癌症的FDG PET/CT支持方向存在明显不一致。

临床应用与阅片要点

  • 作者建议临床医生在实践应用中对这些推荐保持批判性。
  • 作者建议指南制定者采用更严格的制定方法。
  • 作者建议研究者优先研究当前指南所识别的证据空白。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To systematically appraise the methodologies used for guidelines for positron emission tomography (PET) imaging and to compare the consistency of these recommendations.

METHODS: We searched PubMed, EMBASE, four guideline databases, and Google Scholar to identify evidence-based clinical practice guidelines pertaining to the use of PET, PET/computed tomography (CT), or PET/magnetic resonance in routine practice. We assessed the quality of each guideline using the Appraisal of Guidelines for Research and Evaluation II instrument and compared recommendations regarding indications for 18F-fluorodeoxyglucose (FDG) PET/CT.

RESULTS: Thirty-five guidelines for PET imaging, published between 2008 and 2021, were included. These guidelines performed well in the domains of scope and purpose (median 80.6%, inter-quartile range [IQR] 77.8-83.3%) and clarity of presentation (median 75%, IQR 69.4-83.3%), but poorly in applicability (median 27.1%, IQR 22.9-37.5%). Recommendations for 48 indications in 13 cancers were compared. Considerable inconsistencies in the direction of whether to support the use of FDG PET/CT were observed in 10 (20.1%) indications pertaining to 8 cancer types: head and neck cancer (treatment response assessment), colorectal cancer (staging in patients with stages I-III disease), esophageal cancer (staging), breast cancer (restaging and treatment response assessment), cervical cancer (staging in patients with stage < IB2 disease and treatment response assessment), ovarian cancer (restaging), pancreatic cancer (diagnosis), and sarcoma (treatment response assessment).

CONCLUSIONS: Current guidelines for PET imaging vary in methodological quality and provided considerably inconsistent recommendations. Efforts are needed to improve adherence to guideline development methodologies, to synthesis high-quality evidence, and to adopt standard terminologies.

PROTOCOL REGISTRATION NUMBER: PROSPERO CRD42020184965.

CLINICAL RELEVANCE STATEMENT: Guidelines for PET imaging provide considerably inconsistent recommendations and vary in methodological quality. It is suggested that clinicians be critical of these recommendations when applying them in practice, that guideline developers adopt more rigorous development methodologies, and that researchers prioritize research gaps identified by current guidelines.

KEY POINTS: • PET guidelines vary in methodological quality and provided inconsistent recommendations. Efforts are needed to improve methodologies, synthesize high-quality evidence, and standardize terminologies. • Among six domains of methodological quality assessed by the AGREE II tool, guidelines for PET imaging performed well in scope and purpose (median 80.6%, inter-quartile range 77.8-83.3%) and clarity of presentation (75%, 69.4-83.3%), but poorly in applicability (27.1%, 22.9-37.5%). • Among the 48 recommendations (for 13 cancer types) compared, conflicts in the direction of whether to support FDG PET/CT use were observed in 10 (20.1%), for 8 cancer types (i.e., head and neck, colorectal, esophageal, breast, cervical, ovarian, pancreatic, and sarcoma).

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Li, Hou, Wu, et al. Quality and consistency of clinical practice guideline recommendations for PET/CT and PET: a systematic appraisal. Eur Radiol. 2023. PMID: 37314473. doi:10.1007/s00330-023-09786-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。